Aquiline Capital Partners (Aquiline), a private investment firm with over $10bn in AUM, has made a majority investment in PharmaForce, a pharmacy solutions provider to hospitals and health clinics. Financial terms of the deal have not been disclosed.
The provider has delivered 340B administration software to over 280 clients since its inception in 2017 and recently launched a pharmacy benefits management offering.
In a press statement, PharmaForce said that, with Aquiline’s backing, it will “accelerate strategic M&A and continue to expand its product capabilities”.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
Of the $250bn raised since the end of 2019, approximately 40% came through the ultra-high net worth channel. Goldman Sachs has a $1tn-plus private wealth management business focused exclusively on the ultra-high net worth space, with 16,000 clients.
In a statement, Goldman Sachs said: “The environment in 2024 remains uncertain, but we are confident in the state of our portfolio companies and remain resolutely focused on the basics of value creation, good ownership and being thoughtful about exit opportunities.”
source: Private Equity Wire
Can’t stop reading? Read more
Sixth Street-backed Caris Life Sciences targets $5.35bn valuation in US IPO
Sixth Street-backed Caris Life Sciences targets $5.35bn valuation in US IPO Sixth Street-backed...
Advent eyes $5.06bn Spectris takeover in UK’s biggest buyout bid of 2025
Advent eyes $5.06bn Spectris takeover in UK’s biggest buyout bid of 2025 Advent International has...
CalPERS posts 11.3% private equity return as $92bn strategy revamp gains traction
CalPERS posts 11.3% private equity return as $92bn strategy revamp gains traction The California...